New Director for MSU Drug Discovery

MSU Drug Discovery and the Department of Pharmacology and Toxicology are delighted to welcome Dr. Andrea Gonzales to MSU. Andrea will direct the MSU Drug Discovery program. This exciting addition to our team was made possible by the MSU Global Impact Initiative.

Andrea joins us after 10 years at Pfizer and 12 years at Zoetis. In those roles, she led organizations or teams that contributed to numerous drug approvals, including APOQUEL™/APOQUEL CHEWABLE™, a selective Janus Kinase inhibitor, and CYTOPOINT™, a caninized anti-canine IL-31 monoclonal antibody all approved for the treatment of atopic dermatitis in dogs, VIZIMPRO®, an irreversible pan-erbB inhibitor for the first-line treatment of human patients with EGFR-mutated metastatic non-small cell lung cancer, and IBRANCE®, a CDK4/6 inhibitor used to treat HR+, HER2- breast cancer.

Her recent work has focused on biologics and she will be bringing that expertise to MSU Drug Discovery to expand on our existing small molecule portfolio. 

Please join us in welcoming Andrea as the new Director of MSU Drug Discovery.